Format

Send to

Choose Destination
N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Collaborators (343)

Caccavo A, Codutti O, Gelersztein E, Vico M, Zaidman C, Majul C, Balthazar Y, Capiau L, Vrolix M, Vermeersch P, Gotchev D, Todorov G, Tumbev H, Tzekova M, Gronkova N, Dimov B, Nikolaeva A, Devedzhiev T, Mincheva V, D'Ignazio G, Dzongowski P, Elliott T, Hart R, Hoag G, Martinho V, O'Mahony M, Tellier G, Bergeron J, Pandey S, Heaton K, Constance C, Phaneuf DC, Shu D, Narvaez NC, Cañon CO, Cardenas SP, Loayza MS, de Salazar DM, Lopez RB, Gomez JI, Mendoza JA, Cure CC, Ceska R, Zidkova E, Jansky P, Egstrup K, Klausen IB, Lomholdt J, Gislason G, Torp-Pedersen C, Poulsen S, Kuusela M, Kekki S, Nieminen S, Tuomilehto J, Boye A, Bruckert E, Cadinot D, Farnier M, Lejay D, Luc G, Revol T, Schaupp T, Krempf M, Bonnet J, Paillard F, Moulin P, Junggeburth J, Isermann B, Zühlke M, Züchner D, Theis E, Stößel J, König HJ, Rinke A, Piechatzek R, Contzen C, Lappo M, Himpel-Boenninghoff AA, Meissner G, Maus O, Degtyareva E, Schulze ED, Horacek T, Marten I, Becher P, Matoltsy A, Nyirati G, Paragh G, Zilahi Z, Nagy K, Kanakaridisz N, Beke E, Biro J, Schnabel R, Elias M, Gavish D, Francis A, Nseir W, Zimlichman R, Averna M, Pozzi C, Lembo G, Bucci M, Mezzetti A, Rubba P, De Pellegrin AM, Salvioni A, De Cesare N, Briones IR, Campos PF, Rosas EL, Espinosa EV, Salazar MA, Ruiz AB, Furusho LC, Olvera I, Stroes E, van den Berg R, Basart D, Köse V, Kentgens S, Peeters M, Hoogendijk J, Voors-Pette C, Agous I, van Kempen W, Lingan GR, Kooy A, Troquay R, Herrman J, Hoivik H, Langslet G, Norheim P, Risberg K, Høivik HO, Elle S, Derezinski T, Miekus P, Ogorek M, Szymkowiak K, Cesar M, Gawron A, Dabrowska M, Blach E, Konieczny M, Sidor M, Matias F, da Silva PM, Carvalho D, Mendonca I, Andor M, Andrei L, Podoleanu C, Pop C, Chizhov P, Chumakova G, Goloschekin B, Libov I, Paltsman Z, Strutinskiy A, Koziolova N, Breedt J, Ebrahim I, Ellis G, Fulat M, van Rensburg DJ, Raal F, van Dyk C, Vally T, van der Walt E, Kotzé H, Landman C, Tayob M, Caixas A, García LR, Fernandez-Cruz A, Gil-Extremera B, Grijalvo OM, Plana N, Fuentes F, Valdivielso P, Fraile B, Borgencrantz B, Larnefeldt H, Tengmark BO, Eriksson M, Olsson-Önerud Å, Amalyan W, Dyadyk O, Koval O, Kushnir M, Svintsitskiy A, Kovalyov O, Bondarchuk O, Tashchuk V, Barna O, Prokhorov O, Karpenko O, Stanciu D, Pawa R, Balaji H, Doig F, Harvey P, Ranganath L, Massalski W, Hassanin H, Timmis H, Pavel-Knox I, Abdulhakim E, Oyesile B, Horvathova V, Donnachie H, Kondagunta V, Shaw H, Thomas H, Kadr H, Gunstone A, Lip G, Ellery A, Kerrane J, Sarker A, Wong YK, Soran H, Maw K, Andersen J, Blair-Britt L, Huffman C, Kivitz A, Marple R, Patron A, Schear M, Allegar N, Awasty V, Casanova R, Chaykin L, Cohen L, Collins H, Collins G, Elkin G, Reyes H, Feld L, Fuller G, Glover R, Greenwald J, Herrod J, Kaye W, Kimmel M, Kolettis E, Lakin G, Lorch D, Palatnik M, Patel R, Reichman A, Rohlf J, Shockey G, Shore K, Radin D, Alvarado O, Bellingar B, Egelhof R, McKnight T, Plevin S, Pritchard J, Reddy R, Velazquez F, Bolster E, Broker R, Butuk D, Cheung D, Cohen K, Golden G, Murray A, Naccarato T, Uusinarkaus K, Pudi K, Graff A, Blumberg V, Dunn F, Toth P, Anspach R, Chuang R, Meli J, Nevins B, Wayne J, Schmidt L, Levinsky D, Rubino J, Shealy N, Torres D, West J, Jain R, Vardi G, Singh N, Thew S, Lo E, Heitner J, Gerber J, Malik A, Weinstein D, Prashad R, Koren M, Ghitis A, David W, Reis G, Kinzfogl G, Haught H, Kantaros L, O'Dea D, Weiss D, Kassas S, Hunter J, Mollod M, Khan N, Henderson D, Gatien L, Schramm R, Madder R, El Shahawy M, Voyce S, Nadar V, Stich M, Kumar M, Black R, Treasure C, Lebeis M, McCullough P, Lepor N, Moriarty P, Waxler A, Talreja D, Gen M, Dohad S, East C, Conrad G, Asbill B, Roberts J, Robinson J, Zarich S, Davis B, Krolick M, Sherman H, Thompson P.

Author information

1
From the University of Iowa, Iowa City (J.G.R.); Point Médical, Dijon (M.F.), Centre Hospitalier Universitaire de Nantes-Hôpital Nord Laennec, Saint-Herblain (M.K.), University Hospital of Lille, Lille (G. Luc), and Sanofi, Chilly-Mazarin (C.L.) - all in France; Clinique des Maladies Lipidiques de Québec, Quebec, QC, Canada (J.B.); Università di Palermo-Policlinico P. Giaccone, Palermo, Italy (M.A.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.S., J.J.P.K.); Lipid Clinic, Oslo University Hospital, Oslo (G. Langslet); University of the Witwatersrand, Johannesburg (F.J.R.); Cardiovascular Center of Sarasota, Sarasota (M.E.S.), and Jacksonville Center for Clinical Research, Jacksonville (M.J.K.) - both in Florida; Westside Medical Associates of Los Angeles, Beverly Hills, CA (N.E.L.); Regeneron Pharmaceuticals, Tarrytown, NY (R.P.); and Sanofi, Bridgewater, NJ (U.C.).

Abstract

BACKGROUND:

Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.

METHODS:

We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24.

RESULTS:

At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02).

CONCLUSIONS:

Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).

PMID:
25773378
DOI:
10.1056/NEJMoa1501031
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center